A medical abortion, also known as medication abortion, is a type of non-surgical abortion in which medication is used to bring about abortion. An oral preparation for medical abortion is commonly referred to as an abortion pill.
|First use||United States 1979 (carboprost),|
West Germany 1981 (sulprostone),
Japan 1984 (gemeprost),
France 1988 (mifepristone),
United States 1988 (misoprostol)
|Medical abortions as a percentage of all abortions|
|UK: Eng. & Wales||62% (2016)|
|UK: Scotland||83% (2016)|
|United States||30% (2014)|
Medical abortion became an alternative method of abortion with the availability of prostaglandin analogs in the 1970s and the antiprogestogen mifepristone (also known as RU-486) in the 1980s.
For pregnancies of gestational age between 12–14 weeks, the World Health Organization recommends the following medications for abortions:
- oral mifepristone
- oral misoprostol, when mifepristone is not available
Surgical abortion via vacuum aspiration is an alternative option recommended by WHO for pregnancies up to 12–14 weeks in gestational age.
Contraindications to a medical abortion may include:
- previous allergic reaction to one of the drugs involved;
- inherited porphyria;
- chronic adrenal failure;
- ectopic pregnancy
Caution is required in a range of circumstances including:
- long-term corticosteroid use;
- bleeding disorder;
- severe anemia;
- Expected side effects:
- Cramping and vaginal bleeding within 24–48 hours of taking the medication are signs that the treatment is working
- Common side effects:
- Complications that require immediate medical attention:
- Heavy bleeding (enough blood to soak through two sanitary pads in 2 hours)
- Abdominal pain, nausea, vomiting, diarrhea, fever for more than 24 hours after taking mifepristone
- Fever of 100.4 °F or higher for more than 4 hours
- Common side effects:
- abdominal pain
- Gynecological side effects:
- menstrual disorder
Although medical abortion is associated with more bleeding than surgical abortion, overall bleeding for the two methods is minimal and not clinically different. In a large-scale prospective trial published in 1992 of more than 16,000 women undergoing medical abortion using mifepristone with varying doses of gemeprost or sulprostone, only 0.1% had hemorrhage requiring a blood transfusion. It is often advised to contact a health care provider if there is bleeding to such degree that more than two pads are soaked per hour for two consecutive hours.
A retrospective study published in The New England Journal of Medicine in July 2009 of 227,823 women who underwent medical abortion at Planned Parenthood affiliate centers from January 2005 through June 2008, found that the rate of serious infection after medical abortion declined by 93% after a change from vaginal to buccal administration of misoprostol combined with the routine prophylactic administration of doxycycline antibiotics.
Management of prolonged bleedingEdit
According to the 2006 WHO Frequently asked clinical questions about medical abortion, vaginal bleeding generally diminishes gradually over about two weeks after a medical abortion, but in individual cases spotting can last up to 45 days. If the woman is well, neither prolonged bleeding nor the presence of tissue in the uterus (as detected by obstetric ultrasonography) is an indication for surgical intervention (that is, vacuum aspiration or dilation and curettage). Remaining products of conception will be expelled during subsequent vaginal bleeding. Still, surgical intervention may be carried out on the woman's request, if the bleeding is heavy or prolonged, or causes anemia, or if there is evidence of endometritis.
There are three methods for medical abortion:
- Mifepristone followed by misoprostol
- The National Abortion Federation (NAF) recommends a mifepristone and misoprostol combination regimen, wherever mifepristone is legally available and accessible. This is an option for patients with gestations through 70 days. Mifepristone 200 mg is taken and followed by misoprostol 800 mcg buccally, vaginally, or sublingually 24 to 48 hours later. A 2011 systematic review found that it was simpler and equally safe to administer mifepristone in clinic and have the pregnant woman later take misoprostol at home as it was to administer both drugs in the clinic.
- The World Health Organization recommends the combined use of mifeprostone followed by misoprostol for pregnancies of gestational age 9 weeks or less. This combination consists of 200 mg mifeprostone followed by 800mcg of misoprostol to be taken within 24–48 hours. The misoprostol can be administered in the clinic or at home. For pregnancies that are 9–12 weeks of gestational age, the WHO recommends the initial 200 mg mifeprostone dose to be followed by 800mcg misoprostol administered vaginally, which can be repeated every three hours up to 4 total doses. In this case, the misoprostol must be administered in the clinic.
- The early first-trimester medical abortion regimen (200 mg of oral mifepristone, followed 24–48 hours later by 800 mcg of buccal misoprostol) currently used by Planned Parenthood clinics in the United States since April 2006 is 98.3% effective through 59 days' gestation.
- Misoprostol alone
- Methotrexate followed by misoprostol
- Though not a first line choice, a methotrexate/misoprostol combination regimen is appropriate. Methotrexate is given either orally or intramuscularly, followed by vaginal misoprostol 3–5 days later. This is an appropriate option for gestations through 63 days.
- Per the WHO, a methotrexate-misoprostol regimen can also be used; but is not recommended as methotrexate may be teratogenic to the fetus in cases of incomplete abortion. However, this combination is considered more effective than misoprostol alone.
Medical abortion regimens using mifepristone in combination with a prostaglandin analog are the most common methods used to induce second-trimester abortions in Canada, most of Europe, China and India; in contrast to the United States where 96% of second-trimester abortions are performed surgically by dilation and evacuation.
Mifepristone (mif-uh-PRIS-tone) blocks the hormone progesterone, causing the lining of the uterus to thin and preventing the embryo from staying implanted and growing. Methotrexate, which is sometimes used instead of mifepristone, stops the cytotrophoblastic tissue from growing and becoming a functional placenta. Misoprostol (my-so-PROS-tol), a different kind of medication, causes the uterus to contract and expel the embryo through the vagina.
Some pro-life groups claim that the abortifacient effect of mifepristone can be reversed by administering progesterone to the patient. At this time there is no scientifically rigorous evidence that the effects of mifepristone can actually be reversed this way. Even so, several states in USA require providers of non-surgical abortion who use mifepristone to tell patients that reversal is an option. For the first time, a small (forty participant subjects) but rigorous, properly-controlled, double-blind academic clinical trial of the reversal regimen using progesterone is underway, at the University of California at Davis.
|Italy||17% in 2015|
|Spain||19% in 2015|
|Belgium||22% in 2011|
|Netherlands||22% in 2015|
|Germany||23% in 2016|
|United States||30% in 2014|
|England and Wales||62% in 2016|
|France||64% in 2016|
|Iceland||67% in 2015|
|Denmark||70% in 2015|
|Portugal||71% in 2015|
|Switzerland||72% in 2016|
|Scotland||83% in 2016|
|Norway||87% in 2016|
|Sweden||92% in 2016|
|Finland||96% in 2015|
A Guttmacher Institute survey of abortion providers estimated that early medical abortions accounted for 31% of all nonhospital abortions and 45% of nonhospital abortions before 9 weeks' gestation in the United States in 2014.
In the United States in 2009, the median price charged for a medical abortion up to 9 weeks' gestation was $490, four percent higher than the $470 median price charged for a surgical abortion at 10 weeks' gestation. In the United States in 2008, 57% of women who had abortions paid for them out of pocket.
In April 2013, the Australian government commenced an evaluation process to decide whether to list mifepristone (RU486) and misoprostol on the country's Pharmaceutical Benefits Scheme (PBS). If the listing is approved by the Health Minister Tanya Plibersek and the federal government, the drugs will become more accessible due to a dramatic reduction in retail price—the cost would be reduced from between AU$300 and AU$800, to AU$12 (subsidised rate for concession card holders) or AU$35.
On 30 June 2013, the Australian Minister for Health, the Hon Tanya Plibersek MP, announced that the Australian Government had approved the listing of mifepristone and misoprostol on the PBS for medical terminations early in pregnancies consistent with the recommendation of the Pharmaceutical Benefits Advisory Committee (PBAC). These listings on the PBS occurred on 1 August 2013.
- Rowan, Andrea (2015). "Prosecuting Women for Self-Inducing Abortion: Counterproductive and Lacking Compassion". Guttmacher Policy Review. 18 (3): 70–76. Retrieved October 12, 2015.
- Kulier, Regina; Kapp, Nathalie; Gülmezoglu, A. Metin; Hofmeyr, G. Justus; Cheng, Linan; Campana, Aldo (November 9, 2011). "Medical methods for first trimester abortion". Cochrane Database of Systematic Reviews (11): CD002855. doi:10.1002/14651858.CD002855.pub4. PMID 22071804.
- Creinin, Mitchell D.; Danielsson, Kristina Gemzell (2009). "Medical abortion in early pregnancy". In Paul, Maureen; Lichtenberg, E. Steve; Borgatta, Lynn; Grimes, David A.; Stubblefield, Phillip G.; Creinin, Mitchell D. (eds.). Management of unintended and abnormal pregnancy : comprehensive abortion care. Oxford: Wiley-Blackwell. pp. 111–134. ISBN 978-1-4051-7696-5.
- Kapp, Nathalie; von Hertzen, Helena (2009). "Medical methods to induce abortion in the second trimester". In Paul, Maureen; Lichtenberg, E. Steve; Borgatta, Lynn; Grimes, David A.; Stubblefield, Phillip G.; Creinin, Mitchell D. (eds.). Management of unintended and abnormal pregnancy : comprehensive abortion care. Oxford: Wiley-Blackwell. pp. 178–192. ISBN 978-1-4051-7696-5.
- The World Health Organization (2012). "Safe abortion:technical and policy guidance for health systems".
- International Consensus Conference on Non-surgical (Medical) Abortion in Early First Trimester on Issues Related to Regimens and Service Delivery (2006). Frequently asked clinical questions about medical abortion (PDF). Geneva: World Health Organization. ISBN 978-92-4-159484-4.
- "Mifepristone Prescribing Information" (PDF). FDA.
- "Cytotec (misoprostol) Prescribing Information" (PDF). FDA.
- Murray, S; Wooltorton, E (2005). "Septic shock after medical abortions with mifepristone (Mifeprex, RU 486) and misoprostol". CMAJ. 173: 485. doi:10.1503/cmaj.050980. PMC 1188182. PMID 16093445.
- Fjerstad, Mary; Sivin, Irving; Lichtenberg, E. Steve; Trussell, James; Cleland, Kelly; Cullins, Vanessa (September 2009). "Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days". Contraception. 80 (3): 282–286. doi:10.1016/j.contraception.2009.03.010. PMC 3766037. PMID 19698822.
The medical abortion regimen (200 mg of oral mifepristone, followed 24–48 hours later by 800 mcg of vaginal misoprostol) previously used by Planned Parenthood clinics in the United States from 2001 to March 2006 was 98.5% effective through 63 days' gestation—with an ongoing pregnancy rate of about 0.5%, and an additional 1% of patients having uterine evacuation for various reasons, including problematic bleeding, persistent gestational sac, clinician judgment or patient request.
- National Abortion Federation. (2018). Clinical Policy Guidelines for Abortion Care. Retrieved from https://www.prochoice.org
- Ngo, Thoai D.; Park, Min Hae; Shakur, Haleema; Free, Caroline (2011). "Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review". Bulletin of the World Health Organization. 89 (5): 360–370. doi:10.2471/BLT.10.084046. PMC 3089386. PMID 21556304.
- WHO Department of Reproductive Health and Research (2012). Safe abortion: technical and policy guidance for health systems (PDF) (2nd ed.). Geneva: World Health Organization. pp. 1–9, 46. ISBN 978-92-4-154843-4.
- Dunn, Shelia; Cook, Rebecca (January 7, 2014). "Medical abortion in Canada: behind the times". Canadian Medical Association Journal. 186 (1): 13–14. doi:10.1503/cmaj.131320. PMC 3883814. PMID 24277708.
- "Women's Health".
- Hammond, Cassing; Chasen, Stephen T. (2009). "Dilation and evacuation". In Paul, Maureen; Lichtenberg, E. Steve; Borgatta, Lynn; Grimes, David A.; Stubblefield, Phillip G.; Creinin, Mitchell D. (eds.). Management of unintended and abnormal pregnancy : comprehensive abortion care. Oxford: Wiley-Blackwell. pp. 178–192. ISBN 978-1-4051-7696-5.
- "As controversial 'abortion reversal' laws increase, researcher says new data shows protocol can work". Retrieved April 23, 2018.
- "California Board of Nursing Sanctions Unproven Abortion 'Reversal' (Updated) - Rewire". Rewire. Retrieved November 23, 2017.
- Bhatti, KZ; Nguyen, AT; Stuart, GS (November 12, 2017). "Medical Abortion Reversal: Science and Politics Meet". American Journal of Obstetrics and Gynecology. 218 (3): 315.e1–315.e6. doi:10.1016/j.ajog.2017.11.555. PMID 29141197.
- . (December 15, 2016). "Relazione Ministro Salute attuazione Legge 194/78 tutela sociale maternità e interruzione volontaria di gravidanza - dati definitivi 2014 e 2015 [Ministry of Health report implementation Act 194/78 social protection maternity and voluntary interruption of pregnancy - definitive data 2014 and 2015]". Rome: Ministero della Salute [Ministry of Health]. Table 25 - IVG and type of intervention, 2015: mifepristone + mifepristone+prostaglandin + prostaglandin = 17%.
- . (December 30, 2016). "Interrupción Voluntaria del Embarazo; Datos definitivos correspondientes al año 2015 (Voluntary interruption of pregnancy; final data for 2015" (PDF). Madrid: Ministerio de Sanidad, Politica Social e Igualdad (Ministry of Health and Social Policy). Table G.15: 17,916 (sum of the greater of mifepristone or prostaglandin abortions by gestation period) / 94,188 (total abortions) = 19.0%.
- Commission Nationale d'Evaluation des Interruptions de Grossesse (August 27, 2012). "Rapport Bisannuel 2010-2011". Brussels: Commission Nationale d'Evaluation des Interruptions de Grossesse. prostaglandin 0.40% + mifepristone 21.23% = 21.63% medical abortions
- . (February 9, 2017). "Jaarrapportage 2015 van de Wet afbreking zwangerschap [Annual Report 2015 of the Discontinuation of Pregnancy Act]". Utrecht, Netherlands: Inspectie voor de Gezondheidszorg (IGZ) [Health Care Inspectorate], Ministerie van Volksgezondheid, Welzijn en Sport (VWS) [Ministry of Health, Welfare and Sport].
- . (March 9, 2017). "Schwangerschaftsabbrüche 2016 (Abortions 2016)" (PDF). Wiesbaden: Statistisches Bundesamt (Federal Statistical Office), Germany. 20.237% Mifegyne + 3.021% Medikamentöser Abbruch = 23.257% medical abortions
- Jones, Rachel K.; Jerman, Jenna (January 17, 2017). "Abortion incidence and service availability in the United States, 2014". Perspectives on Sexual and Reproductive Health. 49 (1): 17–27. doi:10.1363/psrh.12015. PMC 5487028. PMID 28094905.
96% of all abortions performed in nonhospital facilities × 31% early medical abortions of all nonhospital abortions = 30% early medical abortions of all abortions; 97% of nonhospital medical abortions used mifepristone and misoprostol—3% used methotrexate and misoprostol, or misoprostol alone—in the United States in 2014.
- . (May 30, 2017). "Abortion statistics, England and Wales: 2016" (PDF). London: Department of Health, United Kingdom.
Medical abortion accounted for 72% of abortions under 10 weeks' gestation—in England and Wales in 2016.
- Vilain, Annick (June 26, 2017). "211 900 interruptions volontaires de grossesse en 2016 (211,900 voluntary terminations of pregnancies in 2016)" (PDF). Paris: DREES (Direction de la Recherche, des Études, de l'Évaluation et des Statistiques), Ministère de la Santé (Ministry of Health), France.
- Heino, Anna; Gissler, Mika (March 7, 2017). "Pohjoismaiset raskaudenkeskeytykset 2015 (Induced abortions in the Nordic countries 2015)" (PDF). Helsinki: Terveyden ja hyvinvoinnin laitos (National Institute for Health and Welfare), Finland. ISSN 1798-0887. Appendix table 6. Drug-induced abortions in Nordic countries 1993–2015, %
- . (September 20, 2016). "Relatório dos Registos das Interrupções da Gravidez - Dados de 2015 [Report of the Interruptions of Pregnancy - Data of 2015]". Lisbon: Divisão de Saúde Sexual, Reprodutiva, Infantil e Juvenil [Division of Sexual, Reproductive, Child and Juvenile Health], Direção de Serviços de Prevenção da Doença e Promoção da Saúde [Directorate of Disease Prevention and Health Promotion Services], Direção-Geral da Saúde (DGS) [Directorate-General for Health].
- . (June 13, 2017). "Interruptions de grossesse en Suisse en 2016 (Abortions in Switzerland 2016)". Neuchâtel: Office of Federal Statistics, Switzerland.
- . (May 30, 2017). "Termination of pregnancy statistics, year ending December 2016" (PDF). Edinburgh: Information Services Division (ISD), NHS National Services Scotland.
Medical abortions accounted for 89% of abortions before 9 weeks' gestation in Scotland in 2016.
- Løkeland, Mette; Mjaatvedt, Aase Gunn; Akerkar, Rupali; Pedersen, Yngve; Bøyum, Bjug; Hornæs, Mona Tornensis; Seliussen, Ingvei; Ebbing, Marta (March 8, 2017). "Rapport om svangerskapsavbrot for 2016 (Report on pregnancy terminations for 2016)" (PDF). Oslo: Divisjon for epidemiologi (Division of Epidemiology), Nasjonalt Folkehelseinstitutt (Norwegian Institute of Public Health), Norway. ISSN 1891-6392.
Medical abortions accounted for 90% of abortions before 9 weeks' gestation in Norway in 2016.
- Öman, Maria; Gottvall, Karin (May 10, 2017). "Statistik om aborter 2016 (Statistics on abortions in 2016)" (PDF). Stockholm: Socialstyrelsen (National Board of Health and Welfare), Sweden.
Medical abortions accounted for 94% of abortions before 9 weeks' gestation in Sweden in 2016.
- Heino, Anna; Gissler, Mika (October 20, 2016). "Raskaudenkeskeytykset 2015 (Induced abortions 2015)" (PDF). Helsinki: Suomen virallinen tilasto (Official Statistics of Finland), Terveyden ja hyvinvoinnin laitos (National Institute for Health and Welfare), Finland.
- Jatlaoui, Tara C.; Ewing, Alexander; Mandel1, Michele G.; Simmons, Katharine B.; Suchdev, Danielle B.; Jamieson, Denise J.; Pazol, Karen (November 25, 2016). "Abortion Surveillance — United States, 2013" (PDF). MMWR Surveillance Summaries. 65 (12): 1–44. doi:10.15585/mmwr.ss6512a1. PMID 27880751.
Medical abortions accounted for 22.2% of abortions—and 32.8% of abortions at ≤8 weeks' gestation—in the United States in 2013 that were voluntarily reported to the CDC by 43 reporting areas (excluding California, Florida, Hawaii, Illinois, Louisiana, Maryland, New Hampshire, Tennessee, and Wyoming).
- Fjerstad, Mary; Trussell, James; Sivin, Irving; Lichtenberg, E. Steve; Cullins, Vanessa (July 9, 2009). "Rates of serious infection after changes in regimens for medical abortion". New England Journal of Medicine. 361 (2): 145–151. doi:10.1056/NEJMoa0809146. PMC 3568698. PMID 19587339.
Allday, Erin (July 9, 2009). "Change cuts infections linked to abortion pill". San Francisco Chronicle. p. A1.
- Mindock, Clark (October 31, 2016). "Abortion Pill Statistics: Medication Pregnancy Termination Rivals Surgery Rates In The United States". International Business Times. Retrieved April 19, 2018.
- Jones, Rachel K.; Kooistra, Kathryn (March 2011). "Abortion incidence and access to services in the United States, 2008" (PDF). Perspectives on Sexual and Reproductive Health. 43 (1): 41–50. doi:10.1363/4304111. PMID 21388504.
Stein, Rob (January 11, 2011). "Decline in U.S. abortion rate stalls". The Washington Post. p. A3.
- Jones, Rachel K.; Finer, Lawrence B.; Singh, Shusheela (May 4, 2010). "Characteristics of U.S. abortion patients, 2008" (PDF). New York: Guttmacher Institute.
Mathews, Anna Wilde (May 4, 2010). "Most women pay for their own abortions". The Wall Street Journal.
- Peterson, Kerry (April 30, 2013). "Abortion drugs closer to being subsidised but some states still lag". The Conversation Australia. The Conversation Media Group. Retrieved April 29, 2013.
- WHO Scientific Group on Medical Methods for Termination of Pregnancy (December 1997). Medical methods for termination of pregnancy. Technical Report Series, No. 871. Geneva: World Health Organization. ISBN 978-92-4-120871-0. WARNING: LINK GIVES ONLY THE FIRST PAGE OF THE REPORT; THE REST IS LISTED AS "OUT OF PRINT"
- Royal College of Obstetricians and Gynaecologists (November 23, 2011). The care of women requesting induced abortion. Evidence-based clinical guideline number 7 (PDF) (3rd rev. ed.). London: RCOG Press. Archived from the original (PDF) on May 29, 2012.
- ICMA (2013). "ICMA Information Package on Medical Abortion". Chișinău, Moldova: International Consortium for Medical Abortion (ICMA). Archived from the original on July 10, 2010.
- The official protocol of the clinical trial of the "reversal" regimen is here: https://clinicaltrials.gov/ct2/show/NCT03774745